Pancreatic secretory trypsin inhibitor (PSTI), a product of the pancreatic acinar cells secreted into the pancreatic juice, was first described by Kazal et al.'
Physiologically PSTI has an inhibitory effect on trypsin, and increased serum and urine concentrations have been noted in pancreatic diseases, especially in pancreatitis.
Increased serum concentrations of immunoreactive PSTI have also been noted in gynaecological malignancy,6 " in different malignant' and inflammatory9 diseases and after major abdominal surgery.9 10 is not known at present. It may be that the PSTI immunoreactivity represents a common protease inhibitor activity or that PSTI and a possible pepsin protease inhibitor are immunologically related. The PSTI-like material may also have a throphic effect on gastroduodenal mucosa similar to that shown for epidermal growth factor (EGF).19-21 EGF is structurally related to PSTI22 and has been shown immunohistologically in the Brunner's glands in the duodenum and in the gastric glands but not in the foveolar cells in the stomach.2324 The presence of PSTI-like immunoreactive material has, however, been shown in various parts of the stomach but rarely in the Brunner's glands.
The PSTI immunoreactivity shown in this study may also be of interest in the discussion of the pathogenesis of peptic ulcer disease. Gastric 
